Image-Guided Brachytherapy a Comparison Between 192Ir and 60Co Sources in Carcinoma Uterine Cervix.

Q3 Medicine
The gulf journal of oncology Pub Date : 2022-01-01
Mourougan Sinnatamby, Saravanan Kandasamy, Gunaseelan Karunanidhi, Vijayaprabhu Neelakandan, Seenisamy Ramapandian, Muniyappan Kannan, Elakiya Sampath
{"title":"Image-Guided Brachytherapy a Comparison Between 192Ir and 60Co Sources in Carcinoma Uterine Cervix.","authors":"Mourougan Sinnatamby,&nbsp;Saravanan Kandasamy,&nbsp;Gunaseelan Karunanidhi,&nbsp;Vijayaprabhu Neelakandan,&nbsp;Seenisamy Ramapandian,&nbsp;Muniyappan Kannan,&nbsp;Elakiya Sampath","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Combination of external beam radiotherapy (EBRT) and High Dose Rate (HDR) brachytherapy (BT) with concurrent chemotherapy (Cisplatin 40mg/m2/weekly) is the standard treatment of approach for the carcinoma of uterine cervix. In this study for image based HDR brachytherapy of intracavitary both 192Ir and 60Co sources were used for dosimetry and the dose distribution compared between point doses and volume doses as per the recommendation of ICRU89 and GEC-ESTRO on 3D image based planning. The dosimetry and clinical outcome will decide decisionmaking on choice of radionuclide for HDR brachytherapy of cervix in addition to economic reason.</p><p><strong>Materials and methods: </strong>The Study conducted for 27 patients of cancer cervix stage IIB or IIIB with vaginal involvement limited to the upper third of vagina. All patients underwent concurrent chemoradiation Cisplatin 40mg/m2 weekly throughout EBRT by 3D conformal therapy 46Gy in 23# followed by two fractions of HDR brachytherapy with 9Gy/1Fr. Post implants 3mm slice selection of pelvic CT scans performed with ring applicator in place followed by T2 weighted paracorpal or paracoronal section of MRI imaging. The solid ring applicator (AL13017000) from library used for applicator reconstruction. Initially all plan calculated with TG-43 formalism using 192Ir radionuclide (Varian, GammaMed HDR Plus source) and then modelled 60Co radionuclide (Eckert < Ziegler BEBIG GmbH, Co0. A86) used for dose computation. ICRU89 recommended points and volumes of targets and OARs evaluated and compared.</p><p><strong>Results: </strong>The study concludes that 60Co based point-A, BICRU and RICRU doses showed a comparable result with that of 192Ir HDR source based dosimetry. The volume based criterion for the target such as GTV, CTVHR, CTVIR for D90, D98, V150%and V200% are all within 5% dose level comparing two sources.</p><p><strong>Conclusion: </strong>60Co a viable alternate to 192Ir by taking into consideration frequency of source exchange and cost reserve with comparable dosimetry.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The gulf journal of oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Combination of external beam radiotherapy (EBRT) and High Dose Rate (HDR) brachytherapy (BT) with concurrent chemotherapy (Cisplatin 40mg/m2/weekly) is the standard treatment of approach for the carcinoma of uterine cervix. In this study for image based HDR brachytherapy of intracavitary both 192Ir and 60Co sources were used for dosimetry and the dose distribution compared between point doses and volume doses as per the recommendation of ICRU89 and GEC-ESTRO on 3D image based planning. The dosimetry and clinical outcome will decide decisionmaking on choice of radionuclide for HDR brachytherapy of cervix in addition to economic reason.

Materials and methods: The Study conducted for 27 patients of cancer cervix stage IIB or IIIB with vaginal involvement limited to the upper third of vagina. All patients underwent concurrent chemoradiation Cisplatin 40mg/m2 weekly throughout EBRT by 3D conformal therapy 46Gy in 23# followed by two fractions of HDR brachytherapy with 9Gy/1Fr. Post implants 3mm slice selection of pelvic CT scans performed with ring applicator in place followed by T2 weighted paracorpal or paracoronal section of MRI imaging. The solid ring applicator (AL13017000) from library used for applicator reconstruction. Initially all plan calculated with TG-43 formalism using 192Ir radionuclide (Varian, GammaMed HDR Plus source) and then modelled 60Co radionuclide (Eckert < Ziegler BEBIG GmbH, Co0. A86) used for dose computation. ICRU89 recommended points and volumes of targets and OARs evaluated and compared.

Results: The study concludes that 60Co based point-A, BICRU and RICRU doses showed a comparable result with that of 192Ir HDR source based dosimetry. The volume based criterion for the target such as GTV, CTVHR, CTVIR for D90, D98, V150%and V200% are all within 5% dose level comparing two sources.

Conclusion: 60Co a viable alternate to 192Ir by taking into consideration frequency of source exchange and cost reserve with comparable dosimetry.

影像引导下近距离放疗192Ir与60Co源在宫颈癌治疗中的比较。
简介:外束放疗(EBRT)与高剂量率(HDR)近距离放疗(BT)联合化疗(顺铂40mg/m2/周)是宫颈癌的标准治疗入路。本研究基于图像的腔内HDR近距离放射治疗采用192Ir和60Co源进行剂量测定,并根据ICRU89和GEC-ESTRO关于三维图像规划的推荐,比较点剂量和体积剂量的剂量分布。除经济原因外,剂量学和临床结果将决定宫颈HDR近距离放射治疗选择放射性核素的决策。材料和方法:本研究纳入27例宫颈癌IIB期或IIIB期,阴道受损伤限于阴道上三分之一。所有患者在整个EBRT期间同时接受顺铂40mg/m2 /周的放化疗,在23年进行3D适形治疗46Gy,然后进行两次9Gy/1Fr的HDR近距离治疗。植入物后3mm片选择盆腔CT扫描,环形涂抹器就位,然后进行T2加权腕骨旁或冠状旁MRI成像。实心环涂敷器(AL13017000)来自库,用于涂敷器重建。最初,所有计划都使用TG-43形式计算,使用192Ir放射性核素(Varian, GammaMed HDR Plus源),然后模拟60Co放射性核素(Eckert < Ziegler BEBIG GmbH, co .)。A86)用于剂量计算。ICRU89建议评估和比较目标和桨的点数和体积。结果:基于60Co的a点、BICRU和RICRU剂量与基于192Ir HDR源的剂量测定结果相当。GTV、CTVHR、CTVIR对D90、D98、v150%和v2000%的基于体积的靶标比较,均在5%剂量水平以内。结论:从源交换频率和成本储备两方面考虑,60Co可替代192Ir。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The gulf journal of oncology
The gulf journal of oncology Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
37
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信